



January 25, 2019

Pharmacy Announcement

Pharmacy and Therapeutics (P&T) Committee Makes Changes to Preferred Drug List (PDL) Effective February 1, 2019

On November 15, 2018, the Pharmacy and Therapeutics (P&T) Committee of the Nevada Department of Health and Human Services' Division of Health Care Financing and Policy met to review new and existing therapeutic drug classes on the Nevada Medicaid Preferred Drug List (PDL).

The actions taken by the committee are indicated below. All changes are effective February 1, 2019. The complete PDL is posted on the "[Preferred Drug List](#)" webpage.

Drug Class	Drugs Added As Preferred	Drugs Added As Non-Preferred
Biologic Response Modifiers: Multiple Sclerosis Agents – Specific Symptomatic Treatment	DALFAMPRIDINE QL	AMPYRA® QL
Neurological Agents: Anticonvulsants	APTIOM® EPIDIOLEX®	
Neurological Agents: Anticonvulsants – Benzodiazepines	CLOBAZAM	
Psychotropic Agents: ADHD Agents	ATOMOXETINE	ADZENYS® CLONIDINE HCL ER STRATTERA®